Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 89 entries
Sorted by: Best Match Show Resources per page
Protective Effects of N-acetylcysteine and a Prostaglandin E1 Analog, Alprostadil, Against Hepatic Ischemia: Reperfusion Injury in Rats.

Journal of traditional and complementary medicine

Hsieh CC, Hsieh SC, Chiu JH, Wu YL.
PMID: 24872935
J Tradit Complement Med. 2014 Jan;4(1):64-71. doi: 10.4103/2225-4110.124351.

Ischemia-reperfusion (I/R) injury has a complex pathophysiology resulting from a number of contributing factors. Therefore, it is difficult to achieve effective treatment or protection by individually targeting the mediators or mechanisms. Our aim was to analyze the individual and...

Cite
Hsieh CC, Hsieh SC, Chiu JH, et al. Protective Effects of N-acetylcysteine and a Prostaglandin E1 Analog, Alprostadil, Against Hepatic Ischemia: Reperfusion Injury in Rats. J Tradit Complement Med. 2014;4(1):64-71doi: 10.4103/2225-4110.124351.
Hsieh, C. C., Hsieh, S. C., Chiu, J. H., & Wu, Y. L. (2014). Protective Effects of N-acetylcysteine and a Prostaglandin E1 Analog, Alprostadil, Against Hepatic Ischemia: Reperfusion Injury in Rats. Journal of traditional and complementary medicine, 4(1), 64-71. https://doi.org/10.4103/2225-4110.124351
Hsieh, Cheng-Chu, et al. "Protective Effects of N-acetylcysteine and a Prostaglandin E1 Analog, Alprostadil, Against Hepatic Ischemia: Reperfusion Injury in Rats." Journal of traditional and complementary medicine vol. 4,1 (2014): 64-71. doi: https://doi.org/10.4103/2225-4110.124351
Hsieh CC, Hsieh SC, Chiu JH, Wu YL. Protective Effects of N-acetylcysteine and a Prostaglandin E1 Analog, Alprostadil, Against Hepatic Ischemia: Reperfusion Injury in Rats. J Tradit Complement Med. 2014 Jan;4(1):64-71. doi: 10.4103/2225-4110.124351. PMID: 24872935; PMCID: PMC4032844.
Copy Download .nbib Format: NLM
Differential roles of prostaglandin E-type receptors in activation of hypoxia-inducible factor 1 by prostaglandin E1 in vascular-derived cells under non-hypoxic conditions.

PeerJ

Suzuki K, Nishi K, Takabuchi S, Kai S, Matsuyama T, Kurosawa S, Adachi T, Maruyama T, Fukuda K, Hirota K.
PMID: 24349900
PeerJ. 2013 Nov 28;1:e220. doi: 10.7717/peerj.220. eCollection 2013.

Prostaglandin E1 (PGE1), known pharmaceutically as alprostadil, has vasodilatory properties and is used widely in various clinical settings. In addition to acute vasodilatory properties, PGE1 may exert beneficial effects by altering protein expression of vascular cells. PGE1 is reported...

Cite
Suzuki K, Nishi K, Takabuchi S, et al. Differential roles of prostaglandin E-type receptors in activation of hypoxia-inducible factor 1 by prostaglandin E1 in vascular-derived cells under non-hypoxic conditions. PeerJ. 2013;1:e220doi: 10.7717/peerj.220.
Suzuki, K., Nishi, K., Takabuchi, S., Kai, S., Matsuyama, T., Kurosawa, S., Adachi, T., Maruyama, T., Fukuda, K., & Hirota, K. (2013). Differential roles of prostaglandin E-type receptors in activation of hypoxia-inducible factor 1 by prostaglandin E1 in vascular-derived cells under non-hypoxic conditions. PeerJ, 1e220. https://doi.org/10.7717/peerj.220
Suzuki, Kengo, et al. "Differential roles of prostaglandin E-type receptors in activation of hypoxia-inducible factor 1 by prostaglandin E1 in vascular-derived cells under non-hypoxic conditions." PeerJ vol. 1 (2013): e220. doi: https://doi.org/10.7717/peerj.220
Suzuki K, Nishi K, Takabuchi S, Kai S, Matsuyama T, Kurosawa S, Adachi T, Maruyama T, Fukuda K, Hirota K. Differential roles of prostaglandin E-type receptors in activation of hypoxia-inducible factor 1 by prostaglandin E1 in vascular-derived cells under non-hypoxic conditions. PeerJ. 2013 Nov 28;1:e220. doi: 10.7717/peerj.220. eCollection 2013. PMID: 24349900; PMCID: PMC3845874.
Copy Download .nbib Format: NLM
Clinical and epidemiological characteristics of young patients with Peyronie's disease: a retrospective study.

Research and reports in urology

Paulis G, Cavallini G, Barletta D, Turchi P, Vitarelli A, Fabiani A.
PMID: 26185748
Res Rep Urol. 2015 Jul 09;7:107-11. doi: 10.2147/RRU.S85708. eCollection 2015.

The average age of men affected by Peyronie's disease (PD) is approximately 50-55 years, but cases have been reported even in adolescence. Several studies have already investigated the presence of PD in young men, and these studies reported a...

Cite
Paulis G, Cavallini G, Barletta D, et al. Clinical and epidemiological characteristics of young patients with Peyronie's disease: a retrospective study. Res Rep Urol. 2015;7:107-11doi: 10.2147/RRU.S85708.
Paulis, G., Cavallini, G., Barletta, D., Turchi, P., Vitarelli, A., & Fabiani, A. (2015). Clinical and epidemiological characteristics of young patients with Peyronie's disease: a retrospective study. Research and reports in urology, 7107-11. https://doi.org/10.2147/RRU.S85708
Paulis, Gianni, et al. "Clinical and epidemiological characteristics of young patients with Peyronie's disease: a retrospective study." Research and reports in urology vol. 7 (2015): 107-11. doi: https://doi.org/10.2147/RRU.S85708
Paulis G, Cavallini G, Barletta D, Turchi P, Vitarelli A, Fabiani A. Clinical and epidemiological characteristics of young patients with Peyronie's disease: a retrospective study. Res Rep Urol. 2015 Jul 09;7:107-11. doi: 10.2147/RRU.S85708. eCollection 2015. PMID: 26185748; PMCID: PMC4501350.
Copy Download .nbib Format: NLM
Transurethral Therapy for the Treatment of Erectile Dysfunction: Infant or Dinosaur?.

Molecular urology

Costabile RA.
PMID: 10851315
Mol Urol. 1999;3(2):135-139.

Transurethral pharmacotherapy (TUPT) for the treatment of patients with erectile dysfunction has demonstrated moderate efficacy with an excellent safety profile. Unfortunately, the initial clinical efficacy of transurethral alprostadil (TUA) has led to physician and patient dissatisfaction with this treatment...

Cite
Costabile RA. Transurethral Therapy for the Treatment of Erectile Dysfunction: Infant or Dinosaur?. Mol Urol. 1999;3(2):135-139
Costabile, R. A. (1999). Transurethral Therapy for the Treatment of Erectile Dysfunction: Infant or Dinosaur?. Molecular urology, 3(2), 135-139.
Costabile. "Transurethral Therapy for the Treatment of Erectile Dysfunction: Infant or Dinosaur?." Molecular urology vol. 3,2 (1999): 135-139.
Costabile RA. Transurethral Therapy for the Treatment of Erectile Dysfunction: Infant or Dinosaur?. Mol Urol. 1999;3(2):135-139. PMID: 10851315.
Copy Download .nbib Format: NLM
Current concepts in the management of post-radical prostatectomy impotence.

Current opinion in urology

McMahon CG.
PMID: 17039073
Curr Opin Urol. 1998 Nov;8(6):535-40. doi: 10.1097/00042307-199811000-00010.

Erectile dysfunction after radical retropubic prostatectomy has a multifactorial aetiology, including both neurogenic and vasculogenic factors. Postoperative potency is improved with preservation of the neurovascular bundles in a nerve-sparing procedure. Preoperative and intraoperative identification and preservation of accessory pudendal...

Cite
McMahon CG. Current concepts in the management of post-radical prostatectomy impotence. Curr Opin Urol. 1998;8(6):535-40doi: 10.1097/00042307-199811000-00010.
McMahon, C. G. (1998). Current concepts in the management of post-radical prostatectomy impotence. Current opinion in urology, 8(6), 535-40. https://doi.org/10.1097/00042307-199811000-00010
McMahon, C G. "Current concepts in the management of post-radical prostatectomy impotence." Current opinion in urology vol. 8,6 (1998): 535-40. doi: https://doi.org/10.1097/00042307-199811000-00010
McMahon CG. Current concepts in the management of post-radical prostatectomy impotence. Curr Opin Urol. 1998 Nov;8(6):535-40. doi: 10.1097/00042307-199811000-00010. PMID: 17039073.
Copy Download .nbib Format: NLM
Oral and non-oral combination therapy for erectile dysfunction.

Reviews in urology

Nehra A.
PMID: 17934566
Rev Urol. 2007;9(3):99-105.

An estimated 30 million men in the United States suffer from varying degrees of erectile dysfunction. Increasing age and comorbidities are likely to increase the number of men who are initially refractory or become refractory to phosphodiesterase (PDE)-5 inhibitors,...

Cite
Nehra A. Oral and non-oral combination therapy for erectile dysfunction. Rev Urol. 2007;9(3):99-105
Nehra, A. (2007). Oral and non-oral combination therapy for erectile dysfunction. Reviews in urology, 9(3), 99-105.
Nehra, Ajay. "Oral and non-oral combination therapy for erectile dysfunction." Reviews in urology vol. 9,3 (2007): 99-105.
Nehra A. Oral and non-oral combination therapy for erectile dysfunction. Rev Urol. 2007;9(3):99-105. PMID: 17934566; PMCID: PMC2002499.
Copy Download .nbib Format: NLM
Erectile preservation following radical prostatectomy.

Therapeutic advances in urology

Segal R, Burnett AL.
PMID: 21789097
Ther Adv Urol. 2011 Feb;3(1):35-46. doi: 10.1177/1756287211400492.

Prostate cancer is the most common cancer among men, representing approximately 25% of all new cancer diagnoses in the USA. For clinically localized prostate cancer, the gold standard for therapy remains radical prostatectomy. One of the main adverse effects...

Cite
Segal R, Burnett AL. Erectile preservation following radical prostatectomy. Ther Adv Urol. 2011;3(1):35-46doi: 10.1177/1756287211400492.
Segal, R., & Burnett, A. L. (2011). Erectile preservation following radical prostatectomy. Therapeutic advances in urology, 3(1), 35-46. https://doi.org/10.1177/1756287211400492
Segal, Robert, and Burnett, Arthur L. "Erectile preservation following radical prostatectomy." Therapeutic advances in urology vol. 3,1 (2011): 35-46. doi: https://doi.org/10.1177/1756287211400492
Segal R, Burnett AL. Erectile preservation following radical prostatectomy. Ther Adv Urol. 2011 Feb;3(1):35-46. doi: 10.1177/1756287211400492. PMID: 21789097; PMCID: PMC3126086.
Copy Download .nbib Format: NLM
Analysis of extemporaneous alprostadil formulaions.

International journal of pharmaceutical compounding

Sarver JG, Peng N, Lerdkanchanaporn S, Oravecz-Wilson KI, Alexander KS, Erhardt PW.
PMID: 23985555
Int J Pharm Compd. 1999 Mar-Apr;3(2):148-55.

Twenty-two extemporaneous alprostadil (PGE1) injection solutions samples from five different suppliers and three Caverject (Pharmacia and Upjohn, Inc., Bridgewater, NJ) samples from three different lots, all intended for the clinical treatment of erectile dysfunction, were analyzed to determine PGE1...

Cite
Sarver JG, Peng N, Lerdkanchanaporn S, et al. Analysis of extemporaneous alprostadil formulaions. Int J Pharm Compd. 1999;3(2):148-55
Sarver, J. G., Peng, N., Lerdkanchanaporn, S., Oravecz-Wilson, K. I., Alexander, K. S., & Erhardt, P. W. (1999). Analysis of extemporaneous alprostadil formulaions. International journal of pharmaceutical compounding, 3(2), 148-55.
Sarver, J G, et al. "Analysis of extemporaneous alprostadil formulaions." International journal of pharmaceutical compounding vol. 3,2 (1999): 148-55.
Sarver JG, Peng N, Lerdkanchanaporn S, Oravecz-Wilson KI, Alexander KS, Erhardt PW. Analysis of extemporaneous alprostadil formulaions. Int J Pharm Compd. 1999 Mar-Apr;3(2):148-55. PMID: 23985555.
Copy Download .nbib Format: NLM
Combined treatment of diabetic nephropathy with alprostadil and calcium dobesilate.

Experimental and therapeutic medicine

Qin L, Qin W, Wang J, Lin L.
PMID: 29201206
Exp Ther Med. 2017 Nov;14(5):5012-5016. doi: 10.3892/etm.2017.5115. Epub 2017 Sep 12.

This study investigated the effects of alprostadil combined with calcium dobesilate on the treatment of diabetic nephropathy. We recruited 80 patients with diabetic nephropathy, who were randomly divided into experimental (n=40) and control (n=40) groups. Patients received high-quality low-protein...

Cite
Qin L, Qin W, Wang J, et al. Combined treatment of diabetic nephropathy with alprostadil and calcium dobesilate. Exp Ther Med. 2017;14(5):5012-5016doi: 10.3892/etm.2017.5115.
Qin, L., Qin, W., Wang, J., & Lin, L. (2017). Combined treatment of diabetic nephropathy with alprostadil and calcium dobesilate. Experimental and therapeutic medicine, 14(5), 5012-5016. https://doi.org/10.3892/etm.2017.5115
Qin, Lili, et al. "Combined treatment of diabetic nephropathy with alprostadil and calcium dobesilate." Experimental and therapeutic medicine vol. 14,5 (2017): 5012-5016. doi: https://doi.org/10.3892/etm.2017.5115
Qin L, Qin W, Wang J, Lin L. Combined treatment of diabetic nephropathy with alprostadil and calcium dobesilate. Exp Ther Med. 2017 Nov;14(5):5012-5016. doi: 10.3892/etm.2017.5115. Epub 2017 Sep 12. PMID: 29201206; PMCID: PMC5704275.
Copy Download .nbib Format: NLM
Misdiagnosis And Undertreatment Of Erectile Dysfunction In The Portuguese Primary Health Care.

Sexual medicine

Morgado A, Moura ML, Dinis P, Silva CM.
PMID: 30880000
Sex Med. 2019 Jun;7(2):177-183. doi: 10.1016/j.esxm.2019.01.004. Epub 2019 Mar 14.

INTRODUCTION: The importance of erectile dysfunction (ED) diagnosis and treatment has been highlighted since the early 2000s. However, nearly 20 years after the first phosphodiesterase 5 inhibitor (PDE5i) was marketed, underdiagnosis and undertreatment of ED in the primary health...

Cite
Morgado A, Moura ML, Dinis P, et al. Misdiagnosis And Undertreatment Of Erectile Dysfunction In The Portuguese Primary Health Care. Sex Med. 2019;7(2):177-183doi: 10.1016/j.esxm.2019.01.004.
Morgado, A., Moura, M. L., Dinis, P., & Silva, C. M. (2019). Misdiagnosis And Undertreatment Of Erectile Dysfunction In The Portuguese Primary Health Care. Sexual medicine, 7(2), 177-183. https://doi.org/10.1016/j.esxm.2019.01.004
Morgado, Afonso, et al. "Misdiagnosis And Undertreatment Of Erectile Dysfunction In The Portuguese Primary Health Care." Sexual medicine vol. 7,2 (2019): 177-183. doi: https://doi.org/10.1016/j.esxm.2019.01.004
Morgado A, Moura ML, Dinis P, Silva CM. Misdiagnosis And Undertreatment Of Erectile Dysfunction In The Portuguese Primary Health Care. Sex Med. 2019 Jun;7(2):177-183. doi: 10.1016/j.esxm.2019.01.004. Epub 2019 Mar 14. PMID: 30880000; PMCID: PMC6522934.
Copy Download .nbib Format: NLM
Successful treatment of nonocclusive mesenteric ischemia after aortic valve replacement with continuous arterial alprostadil infusion: A case report.

International journal of surgery case reports

Ogi K, Sanui M, Iizuka Y, Aomatsu A, Nakashima I, Hamamoto K, Okochi T, Lefor AK.
PMID: 28414997
Int J Surg Case Rep. 2017;35:8-11. doi: 10.1016/j.ijscr.2017.03.037. Epub 2017 Mar 30.

INTRODUCTION: Nonocclusive mesenteric ischemia (NOMI) after surgery has an extremely poor prognosis with a mortality rate of 30-100%. We report a patient with NOMI following aortic valve replacement who failed to improve despite continuous intra-arterial infusion of papaverine, but...

Cite
Ogi K, Sanui M, Iizuka Y, et al. Successful treatment of nonocclusive mesenteric ischemia after aortic valve replacement with continuous arterial alprostadil infusion: A case report. Int J Surg Case Rep. 2017;35:8-11doi: 10.1016/j.ijscr.2017.03.037.
Ogi, K., Sanui, M., Iizuka, Y., Aomatsu, A., Nakashima, I., Hamamoto, K., Okochi, T., & Lefor, A. K. (2017). Successful treatment of nonocclusive mesenteric ischemia after aortic valve replacement with continuous arterial alprostadil infusion: A case report. International journal of surgery case reports, 358-11. https://doi.org/10.1016/j.ijscr.2017.03.037
Ogi, Kunio, et al. "Successful treatment of nonocclusive mesenteric ischemia after aortic valve replacement with continuous arterial alprostadil infusion: A case report." International journal of surgery case reports vol. 35 (2017): 8-11. doi: https://doi.org/10.1016/j.ijscr.2017.03.037
Ogi K, Sanui M, Iizuka Y, Aomatsu A, Nakashima I, Hamamoto K, Okochi T, Lefor AK. Successful treatment of nonocclusive mesenteric ischemia after aortic valve replacement with continuous arterial alprostadil infusion: A case report. Int J Surg Case Rep. 2017;35:8-11. doi: 10.1016/j.ijscr.2017.03.037. Epub 2017 Mar 30. PMID: 28414997; PMCID: PMC5394210.
Copy Download .nbib Format: NLM
Comparison between iloprost and alprostadil for protection against ischemia/reperfusion injury in a rat model.

Turkish journal of medical sciences

Çevirme D, Adademir T, Kafalı Başaran E, Şavluk ÖF, Elibol A, Erkanlı Şentürk G, Akkaya H, Yılmaz B.
PMID: 29916227
Turk J Med Sci. 2018 Jun 14;48(3):661-669. doi: 10.3906/sag-1710-74.

Background/aim: Alprostadil and iloprost are successful agents used for both pulmonary hypertension and extremity ischemia treatment. Different systemic effects of these agents may change the preferences of clinical usage. Superiority of preventing ischemia/ reperfusion (IR) injury is a criterion...

Cite
Çevirme D, Adademir T, Kafalı Başaran E, et al. Comparison between iloprost and alprostadil for protection against ischemia/reperfusion injury in a rat model. Turk J Med Sci. 2018;48(3):661-669doi: 10.3906/sag-1710-74.
Çevirme, D., Adademir, T., Kafalı Başaran, E., Şavluk, �. �. F., Elibol, A., Erkanlı Şentürk, G., Akkaya, H., & Yılmaz, B. (2018). Comparison between iloprost and alprostadil for protection against ischemia/reperfusion injury in a rat model. Turkish journal of medical sciences, 48(3), 661-669. https://doi.org/10.3906/sag-1710-74
Çevirme, Deniz, et al. "Comparison between iloprost and alprostadil for protection against ischemia/reperfusion injury in a rat model." Turkish journal of medical sciences vol. 48,3 (2018): 661-669. doi: https://doi.org/10.3906/sag-1710-74
Çevirme D, Adademir T, Kafalı Başaran E, Şavluk ÖF, Elibol A, Erkanlı Şentürk G, Akkaya H, Yılmaz B. Comparison between iloprost and alprostadil for protection against ischemia/reperfusion injury in a rat model. Turk J Med Sci. 2018 Jun 14;48(3):661-669. doi: 10.3906/sag-1710-74. PMID: 29916227.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 89 entries